Denali Therapeutics Inc. (DNLI) develops therapies targeting neurodegenerative diseases. The company owns an impressive pipeline of targeted therapeutic candidates for neurodegenerative diseases. Its recent pipeline progress has been encouraging. Denali’s strategic partnerships with bigwigs like Biogen (BIIB) and Sanofi (SNY) provide funds for pipeline development. Denali and Biogen are developing BIIB122/DNL151, a small-molecule inhibitor, of LRRK2 for Parkinson’s disease (“PD”). Earlier this month, Denali ...